01 Aug 2025

Telios Study

Trial overview

Disease

Myelofibrosis

Sponsor

Enquire

Description

Telios Pharma A Phase 2 Multicenter Study of TL-895 in Subjects with Myelofibrosis, Indolent Systemic Mastocytosis, Monoclonal Mast Cell Activation Syndrome, or Non-Monoclonal Mast Cell Activation Syndrome clinical trial

Study details

For detailed information on this trial, please click here

Trial status

Opening August 2025

Location

Oxford

Principal Investigator

Dr Adam Mead

MBBS, MD, FRCP, FRCPath

Consultant Haematologist